Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24030098 | 0.90 | DRD2 (0.47) | DRD2CACNA1HCD274POLB | |
| SCHEMBL13202614 | 0.85 | DRD2 (0.59) | DRD2CACNA1HHDAC2HDAC8HDAC6 | |
| SCHEMBL31301242 | 0.80 | DRD2 (0.63) | DRD2CACNA1HCD274SIGMAR1TDP1 | |
| SCHEMBL18851321 | 0.80 | DRD2 (0.54) | DRD2CACNA1HHDAC2HDAC8HDAC6 | |
| SCHEMBL24029965 | 0.79 | HDAC2 (0.47) | DRD2CACNA1HHDAC2HDAC8HDAC6 | |
| SCHEMBL24029913 | 0.78 | CTSD (0.38) | DRD2CNR1SIGMAR1TSHRTDP1 | |
| SCHEMBL29263630 | 0.77 | DRD2 (0.62) | DRD2SIGMAR1TDP1 | |
| SCHEMBL21017165 | 0.77 | DRD4 (0.58) | DRD2CACNA1HHDAC2HDAC8HDAC6 | |
| SCHEMBL13609474 | 0.77 | DRD2 (0.60) | DRD2CACNA1HSIGMAR1TDP1 | |
| SCHEMBL22988105 | 0.76 | KMT2A (0.48) | DRD2CACNA1HPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2021227439-A1 | ARYL GLUCOSIDE DERIVATIVE | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | DRD2 1366/4885CACNA1H 1667/4885HDAC2 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.